
    
      A multi-centre, randomised, open-label, cross-over study to evaluate the percentage of false
      negative osteoporosis diagnoses using the standard case-finding procedure as described by the
      Dutch Institute for Health Care (CBO) and to determine the preference of adult osteoporosis
      patients between once monthly dosing of ibandronate (150 mg) and once weekly dosing of
      alendronate (70 mg).
    
  